For solid cancers, other BiTEs have been developed, including those targeting EpCAM (for carcinomas and carcinosarcomas), PSMA (castrate-resistant prostate cancer) and CEA (gastrointestinal adenocarcinomas). This evidence concerns the gene CEACAM5 and carcinoma.